Among several items, Astellas will establish an Innovation Management (AIM) and scale back US subsidiaries, including refocusing of Astellas US Research Institute and closure of OSI Pharmaceuticals and Perseid Therapeutics. In-house fermentation research will be stopped, and the Kashima facility in Osaka will be closed (scheduled during FY2015). Multiple functions of the Kashima facility will be integrated and transferred to appropriate sites, including the Tsukuba Research Center.

Astellas Pharma press release, May 14, 2013